Author

Fabio Salvatore Macaluso 1

1 IBD Unit, 'Villa Sofia-Cervello' Hospital,Palermo,Italy

A PROPENSITY SCORE-MATCHED COMPARISON OF INFLIXIMAB AND ADALIMUMAB IN NAïVE AND NON-NAïVE PATIENTS WITH CROHN'S DISEASE: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

Ambrogio Orlando, Fabio Salvatore Macaluso, Walter Fries, Antonio Carlo Privitera, Maria Cappello, Sebastiano Siringo, Gaetano Inserra, Antonio Magnano, Roberto Di Mitri, Filippo Mocciaro, Nunzio Belluardo, Giuseppe Scarpulla, Giovanni Magri, Antonino Trovatello, Antonio Carroccio, Salvatore Genova, Carmelo Bertolami, Robe

A Propensity Score-Weighted Comparison of Vedolizumab, Adalimumab, and Golimumab in Patients with Ulcerative Colitis: Real-Life Data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

Fabio Salvatore Macaluso, Marco Ventimiglia, Walter Fries, Maria Cappello, Barbara Scrivo, Antonio Magnano, Dario Pluchino, Salvatore Camilleri, Serena Garufi, Roberto Di Mitri, Filippo Mocciaro, Giovanni Magri, Concetta Ferracane, Michele Citrano, Francesco Graziano, Carmelo Bertolami, Sara Renna, Rosalba Orlando, Giulia

EFFICACY OF VEDOLIZUMAB ON INTESTINAL AND ARTICULAR SYMPTOMS: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

Fabio Salvatore Macaluso, Rosalba Orlando, Walter Fries, Mariangela Scolaro, Antonio Magnano, Dario Pluchino, Maria Cappello, Gaetano Cristian Morreale, Sebastiano Siringo, ANTONINO CARLO Privitera, Concetta Ferracane, N Belluardo, Nadia Alberghina, Marco Ventimiglia, Sara Renna, Marta Di Pisa, Mario Cottone, Ambrogio Orla

EFFECTIVENESS AND SAFETY OF USTEKINUMAB FOR THE TREATMENT OF CROHN'S DISEASE IN REAL-LIFE STUDIES: A META-ANALYSIS

Fabio Salvatore Macaluso

LUPUS-LIKE REACTIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ANTI-TNFS ARE RARE BUT INSIDIOUS ADVERSE EVENTS: DATA FROM A LARGE SINGLE-CENTER COHORT

Fabio Salvatore Macaluso

SYSTEMIC CYTOMEGALOVIRUS INFECTION IS A RELEVANT FACTOR AFFECTING SHORT AND LONG TERM OUTCOMES OF PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS: AN 11-YEAR EXPERIENCE

Fabio Salvatore Macaluso, Stella Compagnoni, Sara Renna, Simonetta Maisano, Angelo Casà, Gaspare Solina, Aroldo Gabriele Rizzo, Francesco La Seta, Marco Ventimiglia, Ambrogio Orlando, Mario Cottone

A REAL LIFE COMPARISON OF THE EFFICACY OF ADALIMUMAB VERSUS GOLIMUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS. A MULTICENTER EXPERIENCE FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

Sara Renna, Filippo Mocciaro, Marco Ventimiglia, Fabio Salvatore Macaluso, Rosalba Orlando, Martina Billeci, Maria Cappello, Marco Mendolaro, ANTONINO CARLO Privitera, Concetta Ferracane, Walter Fries, Valentina Pisana, Antonio Magnano, Dario Pluchino, Gaetano Inserra, Giuseppe Scarpulla, Serena Garufi, Antonio Carroccio;;

A PROPENSITY SCORE-WEIGHTED COMPARISON OF VEDOLIZUMAB, ADALIMUMAB, AND GOLIMUMAB IN PATIENTS WITH ULCERATIVE COLITIS: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

Fabio Salvatore Macaluso

Effectiveness and safety of ustekinumab for the treatment of Crohn's disease in real-life studies: a meta-analysis

Fabio Salvatore Macaluso, Marcello Maida, Marco Ventimiglia, Mario Cottone, Ambrogio Orlando

EFFICACY OF VEDOLIZUMAB ON INTESTINAL AND ARTICULAR SYMPTOMS: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

Fabio Salvatore Macaluso

Item 1 - 10 / 16
1
2
We use cookies in order to provide you with a better browsing experience. This includes third-party cookies for traffic analyzation purposes. See here for more information.
OK